Sara Tolaney, MD, MPH, discusses key takeaways from the TROPiCS-02 study of sacituzumab govitecan-hziy for patients with hormone receptor-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.
Sara Tolaney, MD, MPH, associate director of the Susan F. Smith Center for Women’s Cancers; director of Clinical Trials, Breast Oncology; and senior physician at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses key takeaways from the TROPiCS-02 (NCT03901339) study of sacituzumab govitecan-hziy (Trodelvy) for patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.
According to Tolaney, sacituzumab is an effective and safe treatment option for this patient population, thus FDA approval was granted based on findings from the phase 3 study.
Now, experts are further evaluating sacituzumab and trying to move treatment up in earlier settings.
0:10 | I think now seeing with longer follow-up that there continues to be improvement in both progression-free and overall survival, favoring sacituzumab over standard chemotherapy, it reinforces that fact that sacituzumab is a very effective treatment option for patients with pretreated metastatic hormone receptor-positive disease.
0:26 | There's definitely an interest in trying to move sacituzumab up even earlier. Obviously, this was a very pretreated setting with a median of 3 lines of chemotherapy in the metastatic setting and we all would wonder how sacituzumab would do if given earlier. There is a trial called ASCENT-07 [NCT05840211] which is looking at sacituzumab compared with chemotherapy in the first-line of chemotherapy for metastatic hormone receptor-positive disease.
0:52 | There are also ongoing trials looking at sacituzumab in the first-line, metastatic triple negative breast cancer space, so ASCENT-03 [NCT05382299] and ASCENT-04 [NCT05382286], looking at it in the PD-L1-negative population as well as in the PD-L1-positive population. Then, there's even a trial looking at sacituzumab in early breast cancer. That trial is ASCENT-05 [NCT05633654], looking at patients who had preoperative therapy for triple negative breast cancer and have residual disease. Then, they get randomized to get sacituzumab with pembrolizumab [Keytruda] or to get pembrolizumab plus capcitabine per physicians choice.